News from the FDA/CDC

Lorcaserin withdrawn from U.S. market due to cancer risk


 

The Food and Drug Administration asked Eisai to voluntary withdraw the weight-loss drug lorcaserin (Belviq and Belviq XR) on Feb. 13 after a post-marketing trial with more than 12,000 subjects revealed an increased occurrence of cancer.

FDA icon

In a Drug Safety Communication, the agency said “health care professionals should stop prescribing and dispensing lorcaserin to patients. Contact patients currently taking lorcaserin, inform them of the increased occurrence of cancer seen in the clinical trial, and ask them to stop taking the medicine. Discuss alternative weight-loss medicines or strategies with your patients.”

Eisai is complying with the withdrawal request.

The decision is based on the agency’s review of the 5-year trial, which was designed to evaluate cardiac risk with the drug and ended in June 2018. In total, 7.7% of patients randomized to 10 mg lorcaserin twice daily were diagnosed with 520 primary cancers, compared with 7.1% of placebo subjects diagnosed with 470 cancers, over a median follow-up of 3 years and 3 months. There was one additional cancer observed for every 470 patients treated for 1 year.

“There was no apparent difference in the incidence of cancer over the initial months of treatment, but the imbalance increased with longer duration on lorcaserin,” FDA said. Pancreatic, colorectal, and lung cancers were among those diagnosed.

In short, “we believe that the risks of lorcaserin outweigh its benefits based on our completed review of” the data, the agency said. The FDA is not recommending special cancer screenings for patients who have taken lorcaserin.

The action follows an FDA alert in January about a possible elevated cancer risk based on its preliminary analysis of the study.

Patients were also advised Feb. 13 to stop taking the drug and talk to their providers about alternative weight-loss medications and weight-management programs.

They were also told to dispose of the pills at a drug take-back location if available, but if not, to mix them with an “unappealing substance” such as dirt, cat litter, or used coffee grounds; seal them in plastic bag; and put them in the trash.

Recommended Reading

European marketing of Picato suspended while skin cancer risk reviewed
MDedge Family Medicine
Adult survivors of childhood cancer are experiencing fewer major cardiac events
MDedge Family Medicine
Carbs, fat, and mortality: Types matter more than levels
MDedge Family Medicine
New nomogram better predicts bladder cancer risk
MDedge Family Medicine
PSA cancer screening: A case for shared decision-making
MDedge Family Medicine
RCT confirms CT scan screening catches lung cancer early
MDedge Family Medicine
Multiomics blood test outperforms other tests for colorectal cancer screening
MDedge Family Medicine
Uptick in lung cancer in younger women, not related to smoking
MDedge Family Medicine
Funding failures: Tobacco prevention and cessation
MDedge Family Medicine
Data emerging to support personalized nutrition in oncology
MDedge Family Medicine